We previously reported that ADAM10 and ADAM17 metalloproteases mediate resistance to trastuzumab treatment via shedding of HER ligands and the activation of HER receptors in HER2-positive breast cancer cells [21, 22]. The gene discussed is ERBB2; the disease is breast cancer.